Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04305548 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

Study acronym: ISG-MCS
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 31, 2025 to Dec 31, 2026v11
  2. Primary completion date: Aug 1, 2025 to Dec 31, 2025
    • Study completion date: Dec 1, 2025 to Dec 31, 2026
    v10
  3. Primary completion date: Sep 1, 2024 to Aug 1, 2025
    • Study completion date: Dec 31, 2024 to Dec 1, 2025
    v9
  4. Trial status: Active, Not Recruiting to Recruiting
    • Study sites: 6 to 7
    v8
  5. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Start date changed from estimate of Oct 1, 2021 to Sep 14, 2021
    • Site contacts updated at 6 of 6 sites
    v7
Show 5 earlier versionsHide 5 earlier versions
  1. Start date: Jul 1, 2021 to Oct 1, 2021
    • Site contacts updated at 1 of 6 sites
    v6
  2. Start date: May 1, 2021 to Jul 1, 2021v5
  3. Start date: Apr 1, 2021 to May 1, 2021
    • Secondary endpoints: details revised at 1 of 6 entries
    v4
  4. Start date: Dec 1, 2020 to Apr 1, 2021v3
  5. Start date: Sep 1, 2020 to Dec 1, 2020v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Italian Sarcoma Group
11 trials monitored
See 1 trial at risk
Sarcoma
1,026 trials monitored
See 67 trials at risk
Prospective, uncontrolled, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic)
Trial Details
NCT Number NCT04305548
Lead Sponsor Italian Sarcoma Group
Collaborators: PharmaMar
Conditions
(from sponsor)		 Mesenchymal Chondrosarcoma
Related terms Chondrosarcoma, Mesenchymal
Enrollment 16 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov